Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has demonstrated a strong growth trajectory, evidenced by a projected increase in adjusted operating margin from 25.4% in 2024 to 29.7% by 2028, alongside expected operating cash flow exceeding $630 million from 2025 to 2028. Continued demand in the ACTH gel market and successful launches of products like Prucalopride contribute positively to revenue growth, with FY 2025 revenue estimates raised to $269.5 million, reflecting ongoing strength in the company's brand and generic portfolios. Additionally, the avoidance of competitive pressures from potential acquisitions of Mallinckrodt has helped stabilize pricing, bolstering the company’s market position in the orphan drug segment.

Bears say

ANI Pharmaceuticals has experienced a notable decline in revenue within its Brands segment during the second and third quarters of 2024, attributed to unfavorable market conditions affecting certain molecules. Additionally, the company has faced persistent pricing pressures, particularly with Cortrophin, as evidenced by revenue decreases of 12% and 10% in the first quarters of 2023 and 2024, respectively, raising concerns over its future performance. Furthermore, projected revenue for 1Q 2025 is expected to dip significantly over 30% due to seasonal factors and complications related to Medicare access issues, which could adversely impact overall financial stability.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.